NCT00192400View on ClinicalTrials.gov

Trial to Assess the Safety and Tolerability of the Liquid Formulation of CAIV-T in Healthy Children.

PHASE3CompletedINTERVENTIONAL
Enrollment

2,160

Participants

Timeline

Start Date

March 31, 2002

Study Completion Date

November 30, 2002

Conditions
Healthy
Interventions
BIOLOGICAL

CAIV-T

Sponsors

Lead Sponsor

MedImmune LLC
All Listed Sponsors
collaborator

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

lead

MedImmune LLC

INDUSTRY

NCT00192400 - Trial to Assess the Safety and Tolerability of the Liquid Formulation of CAIV-T in Healthy Children. | Biotech Hunter | Biotech Hunter